Ad-hoc News

12.03.2012

The Berlin-based biotechnology company MOLOGEN AG has received approval from the responsible German health authority, the Paul-Ehrlich-Institut, to carry out a phase I/II clinical study with its innovative new MGN1601 cancer medicine. MGN1601 is a...

16.03.2012

The MOLOGEN AG Board of Directors completed a capital increase on June 11, 2010 against cash contributions and excluding subscription rights. On the basis of an authorization granted at the Annual General Meeting, as well as the approval of the...

16.03.2012

The Berlin biotech company MOLOGEN has received approval from the competent German and Austrian health authorities at the Paul Ehrlich Institute and the Federal Office for Safety in Health Care (“Bundesamt für Sicherheit im Gesundheitswesen”),...

16.03.2012

The MOLOGEN AG Board of Directors completed a capital increase on January 7, 2010 against cash contributions and excluding subscription rights. On the basis of an authorization granted at the Annual General Meeting, as well as the approval of the...

       

Share Subscription Facility with US investor GCF

Further Information

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com